205 related articles for article (PubMed ID: 33360197)
1. MCC950, a NLRP3 inhibitor, ameliorates lipopolysaccharide-induced lung inflammation in mice.
Wang L; Lei W; Zhang S; Yao L
Bioorg Med Chem; 2021 Jan; 30():115954. PubMed ID: 33360197
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of combination of anakinra and MCC950 against acute lung injury is achieved through suppression of the NF-κB-mediated-MAPK and NLRP3-caspase pathways.
Wang X; Chen S; Zhao L; Shi X
Int Immunopharmacol; 2021 Aug; 97():107506. PubMed ID: 34022766
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation.
Li Y; Li H; Liu S; Pan P; Su X; Tan H; Wu D; Zhang L; Song C; Dai M; Li Q; Mao Z; Long Y; Hu Y; Hu C
Mol Immunol; 2018 Jul; 99():134-144. PubMed ID: 29783158
[TBL] [Abstract][Full Text] [Related]
4. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
[TBL] [Abstract][Full Text] [Related]
5. Ameliorative effect of selective NLRP3 inflammasome inhibitor MCC950 in an ovalbumin-induced allergic rhinitis murine model.
Zhang W; Ba G; Tang R; Li M; Lin H
Int Immunopharmacol; 2020 Jun; 83():106394. PubMed ID: 32193102
[TBL] [Abstract][Full Text] [Related]
6. The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages.
Zeng W; Wu D; Sun Y; Suo Y; Yu Q; Zeng M; Gao Q; Yu B; Jiang X; Wang Y
Sci Rep; 2021 Sep; 11(1):19305. PubMed ID: 34588488
[TBL] [Abstract][Full Text] [Related]
7. Geranylgeranyl diphosphate synthase 1 knockdown suppresses NLRP3 inflammasome activity via promoting autophagy in sepsis-induced acute lung injury.
Li D; Li C; Wang T; Zhang C; Zhu Z; Zhang G; Fang B
Int Immunopharmacol; 2021 Nov; 100():108106. PubMed ID: 34530204
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, renal damage, and dysfunction in salt-sensitive hypertension.
Krishnan SM; Ling YH; Huuskes BM; Ferens DM; Saini N; Chan CT; Diep H; Kett MM; Samuel CS; Kemp-Harper BK; Robertson AAB; Cooper MA; Peter K; Latz E; Mansell AS; Sobey CG; Drummond GR; Vinh A
Cardiovasc Res; 2019 Mar; 115(4):776-787. PubMed ID: 30357309
[TBL] [Abstract][Full Text] [Related]
9. MCC950 attenuates doxorubicin-induced myocardial injury in vivo and in vitro by inhibiting NLRP3-mediated pyroptosis.
Zhang L; Jiang YH; Fan C; Zhang Q; Jiang YH; Li Y; Xue YT
Biomed Pharmacother; 2021 Nov; 143():112133. PubMed ID: 34474337
[TBL] [Abstract][Full Text] [Related]
10. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of NLRP3 Inflammasome Prevents LPS-Induced Inflammatory Hyperalgesia in Mice: Contribution of NF-κB, Caspase-1/11, ASC, NOX, and NOS Isoforms.
Dolunay A; Senol SP; Temiz-Resitoglu M; Guden DS; Sari AN; Sahan-Firat S; Tunctan B
Inflammation; 2017 Apr; 40(2):366-386. PubMed ID: 27924425
[TBL] [Abstract][Full Text] [Related]
12. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
13. MCC950 attenuated early brain injury by suppressing NLRP3 inflammasome after experimental SAH in rats.
Luo Y; Lu J; Ruan W; Guo X; Chen S
Brain Res Bull; 2019 Mar; 146():320-326. PubMed ID: 30716395
[TBL] [Abstract][Full Text] [Related]
14. Intranasal Application of Budesonide Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Suppressing Nucleotide-Binding Oligomerization Domain-Like Receptor Family, Pyrin Domain-Containing 3 Inflammasome Activation in Mice.
Dong L; Zhu YH; Liu DX; Li J; Zhao PC; Zhong YP; Chen YQ; Xu W; Zhu ZQ
J Immunol Res; 2019; 2019():7264383. PubMed ID: 30937316
[TBL] [Abstract][Full Text] [Related]
15. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
[TBL] [Abstract][Full Text] [Related]
16. MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation.
Jiang M; Li R; Lyu J; Li X; Wang W; Wang Z; Sheng H; Zhang W; Karhausen J; Yang W
J Neuroinflammation; 2020 Aug; 17(1):256. PubMed ID: 32867797
[TBL] [Abstract][Full Text] [Related]
17. Nlrp3 Inflammasome Inhibitor MCC950 Ameliorates Obliterative Bronchiolitis by Inhibiting Th1/Th17 Response and Promoting Treg Response After Orthotopic Tracheal Transplantation in Mice.
Xu KY; Tong S; Wu CY; Ding XC; Chen JL; Ming Y; Wang SH
Transplantation; 2020 Jun; 104(6):e151-e163. PubMed ID: 32108749
[TBL] [Abstract][Full Text] [Related]
18. MCC950, the NLRP3 Inhibitor, Protects against Cartilage Degradation in a Mouse Model of Osteoarthritis.
Ni B; Pei W; Qu Y; Zhang R; Chu X; Wang Y; Huang X; You H
Oxid Med Cell Longev; 2021; 2021():4139048. PubMed ID: 34777685
[TBL] [Abstract][Full Text] [Related]
19. The NLRP3 inflammasome contributes to inflammation-induced morphological and metabolic alterations in skeletal muscle.
Eggelbusch M; Shi A; Broeksma BC; Vázquez-Cruz M; Soares MN; de Wit GMJ; Everts B; Jaspers RT; Wüst RCI
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):3048-3061. PubMed ID: 35978267
[TBL] [Abstract][Full Text] [Related]
20. FSTL1 aggravates OVA-induced inflammatory responses by activating the NLRP3/IL-1β signaling pathway in mice and macrophages.
Wang Y; Zhang D; Liu T; Wang JF; Wu JX; Zhao JP; Xu JW; Zhang JT; Dong L
Inflamm Res; 2021 Jul; 70(7):777-787. PubMed ID: 34076707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
